Etanercept as a TNF-alpha inhibitor depresses experimental retinal neovascularization
- PMID: 33043386
- DOI: 10.1007/s00417-020-04956-6
Etanercept as a TNF-alpha inhibitor depresses experimental retinal neovascularization
Abstract
Purpose: The formation of retinal neovascularization (RNV) is the primary pathological process underlying retinopathy of prematurity (ROP). Previous studies have shown that inflammatory factors are related to the formation of RNV. Tumor necrosis factor-α (TNF-α), as an important factor in the inflammatory response, is involved in the regulation of RNV formation. However, the mechanism through which TNF-α inhibition reduces RNV formation is not fully clarified. Therefore, the purpose of this study was to explore the effect of etanercept, an inhibitor of TNF-α, on RNV, and its possible mechanism.
Methods: In vivo, an oxygen-induced retinopathy (OIR) mouse model was used to determine the effect of etanercept on the formation of RNV by performing immunostaining. The effect of etanercept on tumor necrosis factor receptor-associated factor 2 (TRAF2), pro-angiogenic-related factors, and pro/anti-inflammatory factors in OIR mice was assessed by real-time PCR and Western blotting. In vitro, the effect of etanercept on TNF-α-induced human retinal microvascular endothelial cell tube formation was evaluated by tube formation assays, and the potential mechanism of etanercept was explored by Western blotting.
Results: In vivo, etanercept reduced the area of RNV and decreased the expression of TRAF2 in the OIR mouse model. Etanercept also suppressed the expression of several pro-angiogenic factors and regulated the pro/anti-inflammatory factors. In vitro, etanercept reduced endothelial cell tube formation by inhibiting activation of the NF-κB signaling pathway.
Conclusion: Etanercept can regulate pro/anti-inflammatory factors and reduce the expression of pro-angiogenic factors by inhibiting NF-κB phosphorylation, thereby reducing RNV formation.
Keywords: Etanercept; Retinal neovascularization; Tumor necrosis factor receptor-associated factor 2; Tumor necrosis factor-α.
Similar articles
-
Celastrol inhibits pathologic neovascularization in oxygen-induced retinopathy by targeting the miR-17-5p/HIF-1α/VEGF pathway.Cell Cycle. 2022 Oct;21(19):2091-2108. doi: 10.1080/15384101.2022.2087277. Epub 2022 Jun 13. Cell Cycle. 2022. PMID: 35695424 Free PMC article.
-
The mechanism of CCN1-enhanced retinal neovascularization in oxygen-induced retinopathy through PI3K/Akt-VEGF signaling pathway.Drug Des Devel Ther. 2015 Apr 30;9:2463-73. doi: 10.2147/DDDT.S79782. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 25995618 Free PMC article.
-
Xanthine derivative KMUP-1 ameliorates retinopathy.Biomed Pharmacother. 2023 Sep;165:115109. doi: 10.1016/j.biopha.2023.115109. Epub 2023 Jul 3. Biomed Pharmacother. 2023. PMID: 37406513
-
Animal models of choroidal and retinal neovascularization.Prog Retin Eye Res. 2010 Nov;29(6):500-19. doi: 10.1016/j.preteyeres.2010.05.003. Epub 2010 May 19. Prog Retin Eye Res. 2010. PMID: 20488255 Free PMC article. Review.
-
Long non-coding RNAs in retinal neovascularization: current research and future directions.Graefes Arch Clin Exp Ophthalmol. 2023 Mar;261(3):615-626. doi: 10.1007/s00417-022-05843-y. Epub 2022 Sep 29. Graefes Arch Clin Exp Ophthalmol. 2023. PMID: 36171459 Review.
Cited by
-
Molecular characteristics and pathogenic mechanisms of KPC-3 producing hypervirulent carbapenem-resistant Klebsiella pneumoniae (ST23-K1).Front Cell Infect Microbiol. 2024 Aug 15;14:1407219. doi: 10.3389/fcimb.2024.1407219. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 39211794 Free PMC article.
-
Mechanism of piR-1245/PIWI-like protein-2 regulating Janus kinase-2/signal transducer and activator of transcription-3/vascular endothelial growth factor signaling pathway in retinal neovascularization.Neural Regen Res. 2023 May;18(5):1132-1138. doi: 10.4103/1673-5374.355819. Neural Regen Res. 2023. PMID: 36255003 Free PMC article.
-
Immunotherapy with low-dose IL-2 attenuates vascular injury in mice with diabetic and neovascular retinopathy by restoring the balance between Foxp3+ Tregs and CD8+ T cells.Diabetologia. 2025 Jul;68(7):1559-1573. doi: 10.1007/s00125-025-06412-8. Epub 2025 Mar 25. Diabetologia. 2025. PMID: 40133487 Free PMC article.
-
The Long-Noncoding RNA TUG1 Regulates Oxygen-Induced Retinal Neovascularization in Mice via MiR-299.Invest Ophthalmol Vis Sci. 2022 Jan 3;63(1):37. doi: 10.1167/iovs.63.1.37. Invest Ophthalmol Vis Sci. 2022. PMID: 35084431 Free PMC article.
-
Revamping anti-cGAS-STING therapy via an injectable thermo-responsive supramolecular hydrogel for pathological retinal angiogenesis.Asian J Pharm Sci. 2024 Oct;19(5):100969. doi: 10.1016/j.ajps.2024.100969. Epub 2024 Sep 21. Asian J Pharm Sci. 2024. PMID: 39474128 Free PMC article.
References
-
- Rivera JC, Rabah D, Baraa N et al (2017) Ischemic retinopathies: oxidative stress and inflammation. Oxidative Med Cell Longev 2017:1–16. https://doi.org/10.1155/2017/3940241 - DOI
-
- Hoppe G, Yoon S, Gopalan B et al (2016) Comparative systems pharmacology of HIF stabilization in the prevention of retinopathy of prematurity. Proc Natl Acad Sci U S A 113(18):2516–2525. https://doi.org/10.1073/pnas.1523005113 - DOI
-
- Bancalari A, Schade R (2020, 2020) Update in the treatment of retinopathy of prematurity. Am J Perinatol. https://doi.org/10.1055/s-0040-1713181
-
- Morin J, Luu TM, Superstein R et al (2016) Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics 137(4). https://doi.org/10.1542/peds.2015-3218
-
- Cabral T, Mello LGM, Lima LH et al (2017) Retinal and choroidal angiogenesis: a review of new targets. Int J Retina Vitreous 3(1):31. https://doi.org/10.1186/s40942-017-0084-9 - DOI - PubMed - PMC
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources